London – According to a new study reported by BBC, two doses of either Pfizer and AstraZeneca coronavirus vaccine are highly effective against the B16172 variant, first identified in India. The vaccines were also found to give a similar level of protection against symptomatic disease from the UK variant (B117). The study was led by Public Health England (PHE). It showed that three weeks after the first dose, both vaccines provided only 33 per cent protection against the Indian variant, while it offered 50 per cent effectiveness against the UK variant. These shots are likely to be even more effective at preventing hospital admission and deaths. A total of 12,675 sequenced cases were included between April 5 and May 16. Of these, B117 was detected from 11,621 cases and B16172 from 1,054. The Pfizer vaccine was found to be 88 per cent effective. While AstraZeneca jab was 60 per cent effective against the Indian variant, compared with 66 per cent against the UK variant.